Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Protein From Algae Shows Promise For Stopping SARS
A protein from algae may have what it takes to stop Severe Acute Respiratory Syndrome (SARS) infections, according to new research. A recent study has found that mice treated with the protein, Griffithsin (GRFT), had a 100 percent survival rate after exposure to the SARS coronavirus (SARS-CoV), as compared to a 30 percent survival for untreated mice.

Low Oxygen Levels In Prostate Tumors Can Predict Recurrence: Long-Term Study
Fox Chase Cancer Center researchers have discovered that low-oxygen regions in prostate tumors can be used to predict a rise in prostate-specific antigen (PSA) levels, a marker of tumor recurrence in prostate cancer. The long-term study results were presented at the 2009 American Society of Clinical Oncology annual meeting in Orlando, FL.
News of the day
FDA Approves VYVANSE CII Label Change To Include Supplementary Clinical Data Supporting Efficacy At 13 Hours Postdose In Children Age 6-12 With ADHD
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has approved a change to the prescribing information for its once-daily Attention Deficit Hyperactivity Disorder (ADHD) treatment VYVANSE® (lisdexamfetamine dimesylate) CII, to include supplemental data that demonstrated significant ADHD symptom control in children aged 6 to 12 from the first time point measured (1.5 hours) through 13 hours postdose. VYVANSE is now the first and only oral ADHD stimulant treatment to have 13-hour postdose efficacy data for pediatric patients included in its product labeling.
Endocrinology

Nanopatches To Join The Fight Against Swine Flu

In response to the growing threat of swine flu, a UQ team is applying nanopatch technology to potentially solve the problems associated with vaccinating millions of Australians, thanks to a recently announced government grant. Australian Institute for Bioengineering and Nanotechnology (AIBN) researcher Professor Mark Kendall heads a team testing the potency of mass vaccinations using only a fraction of the standard dose. The project also targets cross-protection by delivering the seasonal vaccine to protect against challenge from the swine A H1N1 influenza virus. Professor Kendall said this research used new nanopatch technology which does away with the needle and syringe and stimulated a potent immune response with a reduced dose. "By accurately and reliably delivering the vaccine to the abundant immune cells, which are located just under of the surface of the skin, we are able to initiate a rapid and powerful immune response from the body, while using considerably less vaccine," Professor Kendall said. "The beauty of the nanopatch is that it could enable large-scale rapid vaccinations in a cost effective manner that is currently not available with the needle and syringe. "The nanopatch could also potentially eliminate needle phobia and the risk of needle stick injuries while being easy and cost-effective to administer" he said. The team includes researchers from the University of Melbourne, the Australian Animal Health lab and one of Professor Kendall"s UQ collaborators, Professor Ian Frazer of UQ"s Diamantina Institute for Cancer Immunology and Metabolic Medicine. The project is supported under the fast-tracked National Health and Medical Research Council"s H1N1 (swine flu) Medical Research Projects. The University of Queensland


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009